In addition, miR-222 can over activate the NF-κB signaling pathway in breast cancer cells by downregulating PDLIM2 expression, leading to increased tumorigenicity in breast cancer cells (Ding et al., 2018). This evidence concerns the gene NFKB1 and breast carcinoma.